Related Experiment Video
Updated: May 6, 2026
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
miR-128-3p Reduces Proliferation and Immune Escape in Acute Myeloid Leukemia Through Targeted Regulation of ZEB1
YanBin Zhang1, DanDong Ma2, XiaoJuan Zhang1
1Department of Hematology, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing City, 100730, China.
Abstract:
microRNAs have received wide attention as potential therapeutic targets. This study explored the action of miR-128-3p in acute myeloid leukemia (AML). miR-128-3p expression in AML was determined by quantitative PCR method. MTT proliferation assay and immunoblot assay were employed to detect proteins related to proliferation and apoptosis in THP-1 cells overexpressing miR-128-3p. RNA immunoprecipitation and dual luciferase reporting system were utilized to verify downstream targets of miR-128-3p. Flow cytometry was conducted to analyze the apoptosis rate and immune escape of THP-1 cells in the T-cell co-culture system. miR-128-3p was lowly expressed in AML patients (reduced by 41.6%). Overexpression of miR-128-3p inhibited THP-1 cell proliferation and immune escape, and stimulated apoptosis. ZEB1 was a downstream target of miR-128-3p, and up-regulation of miR-128-3p inhibited ZEB1 mRNA and protein expression (respectively reduced by 65.8% and 42.0%). Upregulating ZEB1 reversed the inhibitory effect of upregulating miR-128-3p on THP-1 cell proliferation and immune escape. Upregulating ZEB1 promoted PD-L1 protein expression (increased by 0.75-fold). Blocking PD-L1 reversed the promotion of THP-1 cell proliferation and immune escape by upregulating ZEB1. The miR-128-3p/ZEB1/PD-L1 axis is involved in regulating the proliferation and immune escape of AML cells, providing new insights into the molecular mechanism of miR-128-3p in AML and, more importantly, a new target for immunotherapy of AML.
Insights
MicroRNA-128-3p (miR-128-3p) is downregulated in acute myeloid leukemia (AML). Restoring miR-128-3p inhibits AML cell proliferation and immune escape by targeting ZEB1 and PD-L1, offering a new immunotherapy target.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- MicroRNAs (miRNAs) are crucial regulators of gene expression and are implicated in various diseases, including cancer.
- Dysregulation of miRNAs is a hallmark of acute myeloid leukemia (AML), suggesting their potential as therapeutic targets.
Purpose of the Study:
- To investigate the role of miR-128-3p in acute myeloid leukemia (AML).
- To elucidate the molecular mechanisms underlying miR-128-3p's function in AML, focusing on its downstream targets and impact on cell proliferation and immune escape.
Main Methods:
- Quantitative PCR to determine miR-128-3p expression levels in AML patients.
- MTT assay and immunoblotting to assess cell proliferation and apoptosis.
- RNA immunoprecipitation and dual luciferase reporter assays to identify and validate miR-128-3p targets.
- Flow cytometry in a T-cell co-culture system to analyze immune escape and apoptosis rates.
Main Results:
- miR-128-3p expression was significantly reduced in AML patients.
- Overexpression of miR-128-3p suppressed THP-1 cell proliferation and immune escape while promoting apoptosis.
- ZEB1 was identified as a direct downstream target of miR-128-3p, with its expression inversely correlated to miR-128-3p levels.
- ZEB1 upregulation reversed the effects of miR-128-3p, promoting proliferation and immune escape, and increasing PD-L1 expression.
Conclusions:
- The miR-128-3p/ZEB1/PD-L1 axis plays a critical role in regulating AML cell proliferation and immune escape.
- miR-128-3p functions as a tumor suppressor in AML by inhibiting the ZEB1/PD-L1 pathway.
- This axis represents a promising novel therapeutic target for AML immunotherapy.
Related Concept Videos
01:22MicroRNAs
02:23Abnormal Proliferation
01:22MicroRNAs